Individuals & Families Affected by Eczema Unite to Inform Drug Development
August 01, 2019 13:00 ET
|
Asthma and Allergy Foundation of America
Washington, D.C., Aug. 01, 2019 (GLOBE NEWSWIRE) -- Today, five organizations launch a collaborative effort to inform treatment research and development for atopic dermatitis, the most common form...
ASLAN Pharmaceuticals Completes Phase 1 Study for ASLAN004 Targeting Atopic Dermatitis
June 04, 2019 08:00 ET
|
ASLAN Pharmaceuticals Limited
- Final results from single ascending dose study confirm ASLAN004’s favourable tolerability profile, complete inhibition of downstream mediators and potential for monthly dosing SINGAPORE, June ...
ASLAN Pharmaceuticals Acquires Full Global Commercial Rights for ASLAN004 From CSL
May 31, 2019 03:15 ET
|
ASLAN Pharmaceuticals Limited
- Amending their previous agreement, CSL grants ASLAN full global rights to develop, manufacture and commercialise ASLAN004 SINGAPORE, May 31, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals...
Novan to Present Clinical Data at Annual Meeting of the Society for Investigative Dermatology
May 07, 2019 16:15 ET
|
Novan, Inc.
MORRISVILLE, N.C., May 07, 2019 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced that recent data from the Company’s Phase 1b trial with SB414 cream for the...
ASLAN Pharmaceuticals Completes First Part of Single Ascending Dose Study for ASLAN004 Targeting Atopic Dermatitis
March 29, 2019 05:50 ET
|
ASLAN Pharmaceuticals Limited
SINGAPORE, March 29, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN, TPEx:6497), a clinical-stage biopharmaceutical company developing novel therapeutics for global markets, today...
MatriSys Bioscience announces successful FDA Pre-IND review and Phase 2 plans for MSB-01, a revolutionary human-microbiome based treatment for Atopic Dermatitis
March 20, 2019 19:55 ET
|
MatriSys Bioscience
SAN DIEGO, March 20, 2019 (GLOBE NEWSWIRE) -- MatriSys Bioscience, Inc., a clinical stage biotechnology company developing rationally designed microbiome therapeutics to treat the top five skin...
Pruritus Therapeutics Market To Reach USD 17.99 Billion By 2026 | Reports And Data
March 18, 2019 10:27 ET
|
Reports And Data
NEW YORK, March 18, 2019 (GLOBE NEWSWIRE) -- High target disease prevalence, product launches, increasing strategic developments such as partnerships and agreements, favorable research funding...
MatriSys Bioscience Appoints Jennifer Giottonini Cayer to Its Board of Directors
March 11, 2019 03:11 ET
|
MatriSys Bioscience
SAN DIEGO, March 11, 2019 (GLOBE NEWSWIRE) -- MatriSys Bioscience Inc., a clinical-stage specialty biopharmaceutical company developing microbiome-based therapies for the five most common skin...
MatriSys Bioscience Announces Initiation of Corporate IND for its MSB-01 with the FDA and new Microbiome formulation IP filing
January 03, 2019 03:01 ET
|
MatriSys Bioscience
SAN DIEGO, Jan. 03, 2019 (GLOBE NEWSWIRE) -- MatriSys Bioscience, Inc., a leader in the field of microbiome-based therapeutics for the treatment of skin conditions, announced today that it has...
Novan to Present Data from SB414 Phase 1b Atopic Dermatitis Clinical Trial at 3rd Inflammatory Skin Disease Summit
December 11, 2018 08:00 ET
|
Novan, Inc.
Clinical efficacy, as measured by EASI (Eczema Area and Severity Index) changes, was numerically greater for SB414 treated groups compared to vehicle Strong anti-pruritic (itch) effect as measured by...